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Abstract Atherosclerosis and its clinical manifestations are
widely prevalent throughout the world. Atherogenesis is
highly complex and modulated by numerous genetic and
environmental risk factors. A large body of basic scientific
and clinical research supports the conclusion that inflam-
mation plays a significant role in atherogenesis along the
entire continuum of its progression. Inflammation adversely
impacts intravascular lipid handling and metabolism,
resulting in the development of macrophage foam cell,
fatty streak, and atheromatous plaque formation. Given the
enormoushumanandeconomiccostofmyocardialinfarction,
ischemic stroke, peripheral arterial disease and amputation,
and premature death and disability, considerable effort is
being committed to refining our ability to correctly identify
patients at heightened risk for atherosclerotic vascular disease
and acute cardiovascular events so that they can be treated
earlier and more aggressively. Serum markers of inflamma-
tion have emerged as an important component of risk factor
burden. Lipoprotein-associated phospholipase A2 (Lp-PLA2)
potentiates intravascular inflammation and atherosclerosis. A
variety of epidemiologic studies support the utility of Lp-
PLA2 measurements for estimating and further refining
cardiovascular disease risk. Drug therapies to inhibit Lp-
PLA2 are in development and show considerable promise,
including darapladib, a specific molecular inhibitor of the
enzyme. In addition to substantially inhibiting Lp-PLA2
activity, darapladib reduces progression of the necrotic core
volume of human coronary artery atheromatous plaque. The
growing body of evidence points to an important role and
utility for Lp-PLA2 testing in preventive and personalized
clinical medicine.
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Key issues presented
& Currently available methods for estimating cardiovas-
cular risk often underestimate risk, especially in patients
at intermediate risk (two or more risk factors or 10 yr
Framingham risk of 10–20%).
& Approaches for more accurately estimating cardiovas-
cular risk are urgently needed to help identify patients
who warrant more aggressive and comprehensive
treatment of their cardiovascular risk burden in its
entirety.
& Atherosclerosis is a chronic inflammatory disease.
Inflammation creates a toxic environment within the
subendothelial space which stimulates atherosclerotic
plaque development and plaque instability, leading to
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obstruction.
& Markers of inflammation help to refine cardiovascular
risk estimation. As serum levels of Lp-PLA2 rise, the
risk for acute cardiovascular events increases in a
continuous manner.
& Key points for Lp-PLA2: (1) biomarker demonstrates
low biovariability in serum; (2) enzyme plays a
mechanistic role in atherogenesis; (3) serum levels
reflect intravascular inflammation and the presence of
unstable plaque; (4) increased expression of the enzyme
within plaque associated with more complex and
advanced lesions; (5) treatment with a specific molec-
ular inhibitor beneficially impacts necrotic core volume
of coronary plaque in humans; (6) increased serum
levels associated with progressive elevation in risk for
cardiovascular events.
Introduction
Despite enormous strides in the last five decades, acute
cardiovascular events (myocardial infarction, stroke, and
sudden death) remain the principal causes of morbidity and
mortality in industrialized nations. A host of established
and emerging risk factors for cardiovascular disease have
been identified. Among the most important of these and
best characterized epidemiologically are dyslipidemia,
hypertension, age, smoking status, insulin resistance and
diabetes mellitus, and family history for premature coronary
artery disease (CAD). Avariety of approaches to estimating
risk for cardiovascular disease in the primary prevention
setting have been developed [1]. Unfortunately, the use of
quantitative risk estimation is severely underutilized and
leaves many patients undertreated. In addition, although
traditional risk factors for coronary heart disease (CHD) are
well characterized, they do not fully account for risk.
Simplifying risk estimation in primary prevention and
improving the ability to identify patients with established
atherosclerotic disease at heightened risk for either first
time or recurrent events despite appropriate intervention are
important clinical goals. The use of serum biomarkers holds
considerable promise for helping to identify high risk
patients in the contexts of both primary and secondary
prevention [2–4]. Among the most commonly used serum
biomarkers in cardiovascular medicine are those used to
quantify the intensity of host inflammation.
Atherosclerosis and acute coronary syndromes are now
recognized as manifestations of vascular inflammation [5,
6]. Risk factors for CHD promote endothelial dysfunction.
Dysfunctional endothelial cells express adhesion molecules
which promote the binding and influx of inflammatory
white blood cells (T-cells, monocytes, and mast cells) into
the subendothelial space [7]. White blood cells produce
interleukins, cytokines, and reactive oxygen species which
create an inflammatory focus within the arterial wall.
Atherogenic lipoproteins such as low-density lipoprotein
access the subendothelial space where they undergo
trapping within the network of intercellular matrix proteins,
enzymatic oxidative modification, aggregation, and ulti-
mately, uptake by macrophages leading to the development
of foam cells [8, 9]. Atheromatous plaque progressively
expands with formation of a lipid core. As inflammation
worsens and the capacity of phagocytic cells to clear
apoptotic and necrotic debris becomes compromised, a
necrotic core forms [8]. A clinical consequence of steadily
amplified inflammation within plaque is increased risk for
cardiovascular events secondary to weakening and loss of
architectural integrity. This raises the likelihood for sudden
plaque rupture with subsequent formation of overlying
thrombus and arterial luminal obstruction. Atherosclerosis
can therefore be considered an inflammatory disease. There
is mounting evidence that as serum levels of lipoprotein-
associated phospholipase A2 (Lp-PLA2) rise, risk for
myocardial infarction, stroke, and sudden death all
increase significantly [10–13]. This review summarizes
recent findings with this inflammatory biomarker, focusing
on Lp-PLA2 mechanism of action, epidemiologic charac-
terization, and clinical utility as a biomarker for risk
prediction.
The inflammatory biomarker Lp-PLA2
A biomarker is defined as a substance used as an indicator
of a biological state. Through various techniques it is
objectively measured and used to assess normal or
pathogenic biological processes, or of pharmacologic
responses to a therapeutic intervention. By definition it is
critical that this diagnostic tool be relied upon clinically to
improve accuracy of diagnosis, delineate disease subtypes,
monitor disease progression, or improve prognostication
and risk assessment [14]. In addition, a biomarker may
demonstrate treatment efficacy when used with disease
modifying therapies, such as lipid lowering drugs.
Lipoprotein-associated phospholipase A2 (Lp-PLA2)i sa
novel biomarker of vascular-specific inflammation that
provides information about atherosclerotic plaque inflam-
mation and stability. Elevated levels of serum Lp-PLA2 are
indicative of rupture prone plaque and a strong independent
predictor of cardiovascular risk, including coronary artery
disease, MI, and stroke [12, 13]. Lp-PLA2 is associated
clinically with increased CHD risk, and there is a large
body of published evidence from epidemiologic studies
addressing the relationship of Lp-PLA2 a n dr i s ko f
cardiovascular disease [15–17].
28 EPMA Journal (2011) 2:27–38Biologically, Lp-PLA2 is a vascular-specific proinflam-
matory enzyme that operates physiologically in the arterial
intima (Fig. 1). Lp-PLA2 localizes to atherosclerotic plaque,
particularly in plaques with a necrotic core and in ruptured
plaques [18]. High levels of Lp-PLA2 are found in rupture
prone plaques, and it appears Lp-PLA2 is released from
these plaques into the circulation. Lp-PLA2 is primarily
produced by macrophages and then bound to various
lipoproteins, including the ApoB portion of low-density
lipoprotein (LDL) and lipoprotein(a) [19]. Staining of
coronary and carotid tissue demonstrates the presence of
Lp-PLA2 in the thin fibrous cap of rupture-prone plaques,
but not in the early-stage plaques [18, 20]. Coronary and
carotid tissue concentrations of Lp-PLA2 are notably very
high in the rupture-prone shoulder region of thin fibrous
cap atheromas, and histopathologic stains reveal that Lp-
PLA2 co-localizes with macrophages and oxidized LDL in
atherosclerotic coronary and carotid plaques [21].
Lp-PLA2 hydrolyzes phospholipids on oxidized LDL
particles in the subendothelial space (Fig. 2). Lp-PLA2
hydrolyzes the center (sn-2) ester bond of phospholipids
which yields oxidized fatty acids and lysophosphatidylcho-
line (lysoPC), a molecule with a range of potentially
atherogenic effects, including chemoattraction of monocytes,
increased expression of adhesion molecules, and inhibition
of endothelial nitric oxide production [22, 23]. In this
manner, a vicious cycle is set up that leads to recruitment
of monocytes to the intima, where they differentiate to
become macrophages, and, ultimately, foam cells, while at
the same time locally producing more Lp-PLA2. Further-
more, lysoPC has been found to be cytotoxic to vascular
smooth muscle cells and can induce local production of
matrix metalloproteinases (MMP’s), which can thin the
fibrous cap and destabilize the architectural integrity of an
atheromatous plaque through destruction of the collagen
matrix, increasing its propensity to rupture [24].
Fig. 1 Lipoprotein-associated phospholipase A2 and atherogenesis.
Dysfunctional endothelial cells express a variety of adhesion mole-
cules that promote the binding, rolling, and stable arrest of
inflammatory white blood cells, such as T-cells, monocytes, and mast
cells. These inflammatory white cells express a large number of
interleukins and cytokines which help to create an inflammatory nidus
within the vessel wall. Monocytes alter their three-dimensional actin
cytoskeleton and follow a gradient of monocyte chemoattractant
protein-1 down into the subendothelial space by diapadesing between
endothelial cells. Monocytes can transform into resident tissue
macrophages. Low-density lipoprotein particles carry both lipid and
Lp-PLA2 into the arterial wall. Macrophages also produce Lp-PLA2 in
situ within plaque. The lipid in LDL particles undergoes oxidation
mediated by myeloperoxidase, 5′-lipoxygenase, and other agents.
Oxidized LDL stimulates increased expression of scavenging recep-
tors on the surface of macrophages. As lipid is taken up into
macrophages, they are converted into foam cells which can coalesce
to form fatty streaks, which then evolve into atherosclerotic plaques.
Lp-PLA2 specifically hydrolyzes phosphatidylcholine into oxidized
free fatty acid and lysophosphatidylcholine. These lipids potentiate
inflammation and plaque progression. The cap region of a plaque can
become architecturally weakened as matrix metalloproteinases are
produced within plaque. The plaque can rupture with overlying
thrombus formation, resulting in acute myocardial ischemia and an
acute coronary syndrome
EPMA Journal (2011) 2:27–38 29In terms of its utility as a circulating biomarker, Lp-PLA2
produced by activated macrophages and foam cells reenters
the bloodstream and can be quantitatively measured. As
reported by Lavi et al. [19], Lp-PLA2 blood concentrations
sampled simultaneously in the human coronary sinus
demonstrated a net increase in Lp-PLA2 levels as blood
traverses the coronary vascular bed from individuals with
significant atherosclerotic plaque. However, when no coro-
nary plaque is present, a decrease in Lp-PLA2 levels is
found. This study also showed that the lysoPC produced by
Lp-PLA2-mediated hydrolysis of oxidized LDL is highly
associated with coronary artery endothelial dysfunction.
An important unmet clinical need is satisfied by measuring
a circulating biomarker which signals the presence of plaque
prone to rupture, since more than two-thirds of MIs occur in
persons withlessthan50% stenosisoncoronary angiography,
and it was found by Kolodgie et al. [18] that over 75% of
sudden coronary deaths at necropsy were attributable to
plaque rupture and thrombosis. Current well-accepted diag-
nostic tools available to physicians for assessing cardiovas-
cular risk include traditional risk factor counting, a variety of
risk estimation procedures (e.g., Framingham and Reynolds
risk scoring), lipid and lipoprotein measurement, carotid
ultrasound imaging, stress tests, echocardiography, nuclear
imaging, coronary angiography and coronary intravascular
ultrasonography. However, none of these is able to assess
whether a patient has vulnerable, rupture-prone plaques. It is
often discussed that current risk assessment approaches do
not include noninvasive, inexpensive and reliable means of
identifying the potential of plaque rupture; and even though
emerging technologies, such as virtual histology intravascular
ultrasound (IVUS), intravascular ultrasound palpography and
thermography, optical coherence tomography (OCT), or
carotid magnetic resonance imaging (CMRI), may help
assess plaque composition and morphologic characteristics,
these approaches are either invasive or very expensive for
widespread utilization [16, 25].
Lp-PLA2 is a marker of vascular-specific inflammation
and reflects the presence of rupture prone plaque. It is an
independent predictor of cardiovascular risk, over and
above traditional risk factors. However, tests for other
robust biomarkers may be clinically useful in an additive
manner. For example, it has been shown that while these
markers are independent predictors of risk, Lp-PLA2 added
to hs-CRP provides significantly more risk assessment
information over hs-CRP alone. With regard to hs-CRP as a
standalone test, the measured values are quite variable,
requiring several independent measurements over the
course of time to confirm the level, since general
inflammation, infection and adiposity could be driving the
value, while Lp-PLA2 has high specificity and low
biovariability.
Lp-PLA2 as an independent predictor of CVD:
the epidemiologic evidence
Numerous epidemiological studies consistently demonstrate
that an elevated plasma level of Lp-PLA2 is independently
associated with risk of coronary heart disease (CHD) and
ischemic stroke [13, 14, 26–29]. As can be seen from the
studies listed in Table 1 and on Fig. 3, Lp-PLA2 is a robust
independent predictor of risk for the development of future
heart disease and stroke as well as a strong prognostic
Fig. 2 Lp-PLA2 hydrolyzes
oxidized LDL to release
proinflammatory lipids.
Oxidative enzymes can oxidize
phospholipids in LDL particles.
Oxidized phosphatidylcholine
is hydrolyzed by Lp-PLA2 to
release oxidized fatty acid and
lysophosphatidylcholine
30 EPMA Journal (2011) 2:27–38indicator of cardiovascular risk in both men and women with
established cardiovascular disease. While both the enzyme’s
mass and activity have been associated with cardiovascular
risk in human clinical research, at this time only the Lp-
PLA2 mass assay is cleared by the U.S. Food and Drug
Administration for clinical use and carries the CE Mark.
Therefore, this review will tend to use “levels” referring to
circulating mass of the Lp-PLA2 enzyme as detected by
immunoassay.
A large meta-analysis of 32 prospective clinical studies on
Lp-PLA2 was recently published in Lancet [30]. The Lp-
PLA2 Studies Collaboration (LSC) investigated the associa-
tions of Lp-PLA2 mass and activity with cardiovascular
disease (CVD) risk in 79,036 individuals, with over 17,000
outcomes, including risk of coronary heart disease (CHD),
stroke and mortality in various clinical populations, compris-
ing 474,976 person-years at risk. The LSC analyzed
approximately 36,000 individuals with no history of vascular
disease, about 35,000 patients with history of stable vascular
disease and approximately 10,000 patients with recent acute
ischemic events.
There were several key findings in this report: First, Lp-
PLA2 mass and activity levels were found to be significantly
associated with each other as well as with pro-atherogenic
lipoprotein markers such as non-HDL-C and Apo-B.
Second, Lp-PLA2 levels are significantly related to CVD
risk in a continuous, log-linear association. Third, the CVD
risk due to elevated Lp-PLA2 levels in this LSC analysis
(10% per 1-SD increase in Lp-PLA2) is comparable to the
elevated CVD risk associated with two other well established
risk markers: non-HDL-C and blood pressure. Accordingly,
Lp-PLA2 levels provide CVD risk assessment independent
from, and on par with, other risk factors and could provide
distinct insight into the relationship between inflammation,
atherosclerosis and cardiovascular outcomes.
Novel biomarkers such as Lp-PLA2 have recently gained
much attention in the literature, based upon their potential
to be used as an adjunct to traditional risk factors to more
precisely evaluate those at risk for future development of
cardiovascular disease. The need to improve the accuracy
of conventional risk prediction models is particularly
important among patients with intermediate risk. This
group is often comprised of persons with imprecisely
identified cardiovascular risk for whom treatment decisions
are often uncertain.
Improving the prediction of cardiovascular disease risk:
value of Lp-PLA2 as an adjunct to traditional risk
factors
A recently published paper examining area under the
curve (AUC) of receiver operating characteristic curves
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EPMA Journal (2011) 2:27–38 31(ROC) reported that novel markers such as hs-CRP,
MPO and Lp-PLA2 provide little or no additional value to
traditional risk factors in improving the prediction of
future cardiovascular disease risk [31]. This statistical
approach, commonly referred to as the c-statistic,i sn o t
the optimal test in assessing a biomarker’s ability to
predict an individual’s future CVD risk. For example,
studies have shown that even well accepted traditional risk
factors such as smoking, dyslipidemia, and hypertension
have only marginal impact on the c statistic [28]. As
pointed out by Cook [32], a better technique to determine
the value of novel biomarkers in a clinical setting is to
determine whether a biomarker or series of biomarkers
added to traditional risk factors more accurately stratify
individuals into higher or lower risk categories, where
therapeutic treatment strategies are dictated based upon
determined risk level. Nambi and co-workers examined
the ability to reclassify individuals into low-, moderate-,
or high-risk categories compared to traditional risk factors,
based upon Lp-PLA2 and hs-CRP levels [33]. Low risk
was defined as less than a 2% risk of suffering an ischemic
stroke in 5 years, moderate risk 2–5%, and high risk
greater than 5%. Traditional risk factors used to initially
classify risk level included age, gender, smoking status,
systolic blood pressure, use of hypertensive medication, total
cholesterol, HDL-cholesterol, and diabetes status. Initial
classification demonstrated that 86% of the participants
examined were low risk, 11% were intermediate and 3%
wereclassifiedashighrisk.Mostrevealing,theadditionofhs-
CRP and Lp-PLA2 reclassified approximately 39% of the
intermediate-risk category (28% reclassified to a lower risk
and 11% reclassified to a higher risk).
Clinical use of Lp-PLA2 measurements: expert
recommendations
Consensus expert panel recommendations advocate for the
measurement of Lp-PLA2 as an adjunct to traditional risk
factor assessment to improve the prediction of cardiovas-
cular risk [34]. It is recommended that Lp-PLA2 testing be
performed in patients at moderate risk, those defined as
apparently healthy with two or more traditional risk factors
or a 10-year Framingham risk score of 10–20%, as well as
high risk, those with established CHD or CHD risk
equivalents, who will benefit from more aggressive lifestyle
changes and lipid-modifying therapies (Fig. 3). The
LpPLA2 cut point, or clinical decision threshold, for risk
Fig. 3 Epidemiologic evidence demonstrates the clinical utility of Lp-PLA2. More than two dozen clinical studies demonstrate the utility of Lp-
PLA2 and are peer-reviewed and published [16]
32 EPMA Journal (2011) 2:27–38reassignment is >200 ng/mL. The consensus panel agreed
to this threshold based upon review of Lp-PLA2 studies
[28, 35, 36] which demonstrated a sufficient increase in the
risk of cardiovascular events above this level to warrant
more aggressive patient management. Patients at moderate
risk with Lp-PLA2 levels >200 ng/mL are reclassified as
having high CHD risk status, while those persons with
known CHD or CHD risk equivalent and elevated levels of
Lp-PLA2 are reclassified as very high risk (Fig. 4).
In clinical “real world” scenarios and general practice, it
has been found that until such time that a much larger
database is evaluated, it is perhaps more appropriate to also
add “borderline” Lp-PLA2 levels to the continuum of
clinical decision-making. Many clinical labs utilize 200–
235 ng/mL as the borderline range, based on the consensus
panel’s 200 ng/mL and the 235 ng/mL median from
reference interval studies of normal healthy individuals.
Values obtained in this range would then be weighed with
other patient data, such as clinical history, physical findings
and cardiovascular test results to more appropriately
classify a patient’s cardiovascular risk and help decide on
appropriate intensity of therapy.
Lp-PLA2 levels and lipid lowering therapies
A clinician can use Lp-PLA2 data to take action and effect
change in a patient’s risk factors and vascular inflammatory
status. Once an elevated Lp-PLA2 result is identified, the
modifiable risk factors that contribute to vascular inflam-
mation should and can be significantly improved. These
include physical inactivity, excess body fat, smoking, lipids
and high blood pressure, and they can be modified through
lifestyle, diet and exercise changes, as well as through the
use of prescription and other medications to reduce future
CVD risk [37, 38]. Tracking the changes in these
modifiable risk factors provides a good indication of future
CVD risk. While Lp-PLA2 values do not change drastically
over short time periods, they are beneficially affected by
treatment regimens over several weeks to months. While
more research is required to definitively demonstrate Lp-
PLA2 as a therapeutic target, changes in Lp-PLA2 as
surrogate marker of plaque stability and vascular inflam-
mation provides potentially one of the best indications of
efficacy of treatment and reduction in CVD risk. In most
major statin trials, even a very aggressive reduction of LDL
levels left a substantial residual risk of CV events [39].
Assessment of post-treatment Lp-PLA2 levels may help
identify those patients with the greatest remaining residual
risk. Studies are underway to determine how to best use
serial measurements in the course of patient assessment and
treatment.
In published reference interval studies, Lp-PLA2 levels
range from 120 to 342 ng/mL for women and 131 to
376 ng/mL for men, in the central 90th percentile [40].
While more research is required to demonstrate Lp-PLA2
as a therapeutic target, traditional lipid lowering medi-
cations such as statins, fibrates, niacin, and omega-3 fish
oil have been shown to significantly reduce plasma
concentrations of Lp-PLA2. For example, statins and
fibrates reduce Lp-PLA2 by as much as 30%. Among
persons already treated with a statin, omega-3 fish oil
Fig. 4 Algorithm for Lp-PLA2 screening and utility for refining
cardiovascular risk estimation. It is not recommended that Lp-PLA2 be
measured in patients at low risk for cardiovascular disease (one or
fewer risk factors). Patients with two or more risk factors (10 year
Framingham risk score of 10–20%) are optimal candidates for Lp-
PLA2 screening. If the serum level of this enzyme is <200 ng/mL,
then their level of risk requires no further adjustment. However, if the
serum level of Lp-PLA2 is >200 ng/mL, then the patient is reassigned
to high risk status and the LDL-C and non-HDL-C targets are adjusted
to <100 mg/dL and <130 mg/dL, respectively. Among patients who
are high risk (established CHD, diabetes mellitus, abdominal aortic
aneurysm, peripheral vascular disease, symptomatic carotid artery
disease, or a 10 year Framingham risk score >20%), consideration can
b eg i v e nt of u r t h e rr e f i n i n gr i s ke s t i m a t i o nw i t ha nL p - P L A 2
measurement. If the patient’s serum Lp-PLA2 measurement >200 ng/
ml, then the patient can be reclassified as very high risk, and the LDL-
C and non-HDL-C targets should be <70 mg/dL and <100 mg/dL,
respectively. Reproduced with permission from [34]
EPMA Journal (2011) 2:27–38 33therapy and extended release niacin reduce Lp-PLA2 by
13% and 20%, respectively [41–44]. While the mechanism
by which these compounds reduce Lp-PLA2 levels
remains somewhat speculative, it is thought that the drug
induced reductions in plasma concentrations of apoB
containing lipoproteins as well as a transfer of the Lp-
PLA2 enzyme from apoB containing lipoproteins to HDL
contribute to the overall reductions that are routinely
observed [43].
While lipid modifying medications can have a
profound effect on circulating lipoprotein levels, and it
is known that Lp-PLA2 is predominantly associated with
LDL, the therapeutic reduction in LDL does not fully
explain the reduction in Lp-PLA2.D a t af r o mt h e
Pravastatin Inflammation CRP Evaluation (PRINCE) trial
demonstrated that Lp-PLA2 r e d u c t i o nb ys t a t i nt h e r a p yi s
only associated with LDL lowering by statin therapy by
about 6% (R
2=0.06) [45]. It should be reinforced that
while Lp-PLA2 is not currently FDA-approved as a direct
target of therapy, changes in Lp-PLA2 potentially pro-
vides one of the best indications of efficacy of treatment
in improving plaque stability and reduction of vascular
inflammation.
Darapladib, an orally available, small molecule drug that
specifically inhibits Lp-PLA2 in a dose-dependent fashion,
is currently in advanced stages of clinical development.
Preclinically, it has been shown to reduce atheroma
lysophosphatidylcholine content and expression of multiple
genes associated with macrophage and T-lymphocyte
functioning, with considerable decrease in plaque and
necrotic core area [46]. The goal for this drug is to become
an anti-atherosclerotic therapy complementary to current
lipid-modifying therapies (e.g. statins), that addresses
residual cardiovascular risk beyond traditional targets and
therapies [47]. While enzyme activity is rapidly and directly
inhibited by darapladib, it is still unclear what effects this
may have on enzyme mass. Longer term follow up of
patients on inhibitor therapy will be required to ascertain its
quantitative effect on the Lp-PLA2 protein.
One of the first published clinical studies performed in
humans with darapladib evaluated subjects with stable
CHD or a CHD risk equivalent who were on aggressive
lipid-lowering therapy with atorvastatin 20 or 80 mg per
day and were randomized to placebo or darapladib 40, 80,
or 160 mg/d [48]. Darapladib treatment resulted in a dose-
dependent decrease in Lp-PLA2 activity by up to 66% in
the 160 mg group as compared with placebo. Furthermore,
treatment with darapladib (160 mg) resulted in additional
lowering of other inflammatory biomarkers: C-reactive
protein (CRP) levels were lowered by 20%, despite already
modest baseline CRP levels, and darapladib also reduced
interleukin-6 (IL-6) levels. However, levels of myeloper-
oxidase (MPO) and matrix metalloproteinase-9 (MMP-9)
were not affected by darapladib at the doses tested. In
addition, darapladib was shown to produce substantial
additional reductions in Lp-PLA2 activity even when added
to intensive atorvastatin therapy [49]. Since the drug was
well tolerated and the initial study did not reveal any
adverse clinical events or unexpected laboratory values, the
inhibitor was moved into further clinical development.
The Integrated Biomarker and Imaging Study-2 (IBIS-
2) randomized 330 patients with angiographically demon-
strated coronary disease to 160 mg/d of darapladib versus
placebo for 12 months and then reassessed coronary
atheroma volume and plaque characteristics by intravas-
cular ultrasound with virtual histology [50]. In the IBIS-2
study, a 59% reduction in Lp-PLA2 activity was shown,
but without change in hs-CRP. Importantly, the necrotic
core volume increased significantly (p=0.009) in the
placebo group, whereas this increase was halted in the
darapladib group (p=0.71 from baseline). This progres-
sion versus stabilization of necrotic core volume resulted
in a significant treatment difference of −5.2 mm
3 (p=
0.01). However, these compositional changes within the
plaque occurred without a significant treatment difference
in total atheroma volume or degree of calcification (P=
0.95). Based on these results, it was decided to move
forward with a large outcomes trial: the Stabilization of
Atherosclerotic Plaque by Initiation of Darapladib
Therapy (STABILITY) trial.
The STABILITY trial is well underway to enrolling
15,500 patients with stable coronary disease, already taking
statins, and randomizing them to 160 mg/d of darapladib
orally versus placebo for 3 years [51, 52]. The primary end
point is a composite of major adverse cardiovascular
events, including cardiovascular death, nonfatal myocardial
infarction, and nonfatal stroke. Another pivotal clinical trial
with darapladib, the Stabilization of Plaques Using
Darapladib-Thrombolysis in Myocardial Infarction 52
(SOLID-TIMI 52) trial, has just begun recruitment and
will enroll 11,500 acute coronary patients to evaluate
similar dose and endpoints as STABILITY [53].
The Lp-PLA2 inhibitor trials underline the importance
of going beyond traditional risk factor treatment in
patients with CAD. In many previous outcomes studies,
a large amount of residual risk was seen; this was true
even in trials where these risk factors were treated
intensively. While cardiovascular risk was often reduced
by 25–35% in major statin trials (e.g. 4S, WOSCOPS,
LIPID, PROSPER, ASCOT), 65–75% of events were not
prevented. This is the residualr i s kn o ta d d r e s s e db ys o l e l y
assessing traditional risk factors. Lp-PLA2 measurements
constitute a valuable means by which to identify patients
who warrant aggressive, comprehensive risk factor iden-
tification and management or further intensification of
ongoing therapy.
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medicine today
Lp-PLA2 testing has demonstrated an important positive
effect on management of patientswith cardiovascular risk and
associated therapeutic decisions. These therapeutic decisions
may include lifestyle modifications and drug therapy, as well
as the respective intensities of each therapy. These interven-
tions by the healthcare practitioner can be personalized to the
individual according to their Lp-PLA2 levels at presentation
and followed over time with serial measurements.
The following case history is presented as illustrative of
the role of Lp-PLA2 testing in preventive and personalized
clinical medicine:
A new patient presented to her physician for a first visit
on November 19 of last year. This nominally healthy
48 year old woman presented with the chief complaint of
desiring her blood pressure checked because she had noted
that since the previous summer it had been high on
numerous self-checks (i.e. 140/90, 147/90, 155/101, 156/
99, 146/96 148/98, 152/103 mmHg). She had been
checking her blood pressure twice per day since then,
finding it ranged from 126–155/87–104 mmHg (systolic/
diastolic), despite her reporting that it had always been
“good” in the past. She is a regular and moderate exerciser
with a BMI under 25, nonsmoker, non-diabetic, has an
excellent and healthy diet, has one cup of coffee per day,
does not drink alcohol, has no immune disease, no sleep
apnea, and takes no medications. She works as an office
manager, is married with two children ages 18 and 22. She
sees her gynecologist annually for recommended screening
and exams. Her family history is significant for CAD, with
her father having had two MI’s in his late fifties and then
triple coronary artery bypass surgery in his sixties, although
it should be noted this does not meet NCEP criteria for the
patient. Her father and sister have been diagnosed with
hypertension, her maternal grandmother had a stroke, and
the patient’s sister, who was overweight and smoked, had a
stroke the prior year at age 50. The patient’s nephew has
diabetes mellitus. Review of systems revealed an otherwise
healthy woman, but her heart “feels fluttery” at times.
Physical exam was normal, revealing height of 61 in.,
weight 112 lb, BMI 21.2, blood pressure (BP) 142/
82 mmHg, respiratory rate (RR) 16 per minute, heart rate
(HR) 64 beats/minute. Her electrocardiogram was normal,
and her chest x-ray from the prior year was normal.
This patient’s Framingham Risk Score is very low, as are
her traditional risk factors, and she was noted to already be
maintaining a healthy lifestyle and diet. The physician’s
plan included drawing blood for metabolic profile, TSH
and comprehensive lipid panel (VAP, Atherotech), Lp-
PLA2 (PLAC test), and AST/ALT, and follow up in a few
weeks to go over the results. Additionally, the physician
started the patient on the ACE inhibitor ramipril 5 mg daily
for her hypertension.
On the patient’s second visit a month later to follow up on
the labs and ramipril response, her blood pressure was found to
have decreased, and her vital signs at that time were: BP 132/
82, RR 16, HR 66. The VAP lipid panel showed: total
cholesterol (TC) = 174, triglycerides (TG) = 78, direct LDL
cholesterol = 97, non-HDL cholesterol = 112, HDL = 62,
lipoprotein(a)-cholesterol = 7, IDL= 7, VLDL= 15, VLDL3 =
9, LDL density pattern A, LDL3–4 = 52, LDL1–2 = 32,
apolipoprotein B (ApoB) = 77, apolipoprotein A1 (ApoA1) =
159, with ApoB/ApoA1 ratio = 0.48. These values from the
VAP comprehensive lipid panel all were normal and favorable.
Other labs: glucose = 97, hemoglobin A1c = 5.5%, insulin 9.5,
TSH 1.5, ALT/AST19/22,CK 70,BUN 10,andcreatinine 0.9.
Further advanced panel testing showed: hs-CRP = 0.9,
homocysteine = 5.0, NT-proBNP = 36, vitamin D level =
34.8, ApoE3/E3 (most common), cystatin C = 0.66, and Lp-
PLA2 = 269.8 (elevated).
The physician’s assessment and plan at this second visit
were based on considering the patient’s positive family
history of CVD (stroke in smoker, overweight sister, and
father with MI, CABG) and notably her elevated Lp-PLA2
level. Her comprehensive lipid panel (VAP) was noted to be
quite favorable, with lipoproteins and apoliporoteins all
well into the desired range as recommended by clinical
guidelines, and furthermore her blood glucose, thyroid
function tests and hs-CRP were all normal. However, the
one laboratory test result that was found to be abnormal
was her elevated Lp-PLA2 (PLAC) concentration, with a
value of 270 ng/mL. Lp-PLA2 values over 200 ng/mL and
especially over 235 ng/mL are associated with enhanced
cardiovascular risk, as discussed in the above sections.
Although her Framingham Risk Score and Reynolds Risk
Score, with CRP and family history additions, were still
very low, it was called into question whether this patient
was truly low risk, given the positive inflammatory plaque
signal of significantly elevated Lp-PLA2. It was also noted
that since her HDL (62 mg/dL) was favorable, the concept
of “dysfunctional HDL” was considered, which is compatible
with elevated Lp-PLA2 and vascular specific inflammation.
As has been discussed above, at this point it would be
reasonable to take more aggressive action to further assess
this patient. The next step in the plan was to obtain a carotid
ultrasound-carotid intima-media thickness assessment
(CUS/CIMT).
The patient had a third visit about 6 weeks later to follow
up on progress with antihypertensive medication and
review the CUS/CIMT results. Her blood pressure had
improved with ramipril 5 mg/day, with vital signs at this
visit of: BP 112/72 mm/Hg, HR 64, RR 16. The CUS/
CIMT was performed after her previous visit, resulting in
the following data: average IMT = 0.585 mm, with intimal
EPMA Journal (2011) 2:27–38 35age suggesting 48 for population demographic (patient actual
age is 48 years old); the left carotid bulb showed a 2.3 mm
heterogeneous mixed plaque, which is of moderate size. The
physician’s assessment and plan at this third visit noted that
this was an abnormal CUS/CIMT with atherosclerosis, and
the patient was started on a statin medication, with lab tests to
be repeated in 3 months.
On the patient’s fourth visit approximately 3 months
later in June of this year, her vitals were noted as BP 132/
82, HR 80, RR 16, and her medications were noted as
simvastatin 20 mg qhs and ramipril 5 mg/day. Her new lab
results on statin therapy were: total cholesterol = 143, direct
LDL-C = 59, non-HDL-C = 72, TG = 65, HDL-C = 71,
VLDL = 8, LDL3–4 = 35, LDL1–2 = 10, pattern A, ApoB =
52, ApoA1 = 177, with ApoB/ApoA1 ratio = 0.29, and
AST/ALT 27/23. Notably her Lp-PLA2 level decreased to
165.6 ng/mL from 269.8 ng/mL about 6 months earlier.
This fascinating case history demonstrates how Lp-PLA2
testing can have great utility in the personalized approach to
preventive cardiovascular medicine. It proved to be an
abnormal indicator in an otherwise spotless record, suggesting
further clinical workup was warranted, leading to more
aggressivetreatmentandvigilance,culminatinginanexcellent
response in an otherwise very healthy middle aged woman.
While sometimes multiple atherosclerosis signals present
themselves in concert to indicate progressing CVD, this
particular case demonstrates how using Lp–PLA2 testing
m a yi d e n t i f yt h e“hot signal” as manifest by the inflamed
plaque in a key artery. This setting is initially a call for further
assessment, then becoming actionable with drug and
other therapy, and finally it can be monitored with follow
up Lp-PLA2 testing.
Conclusions
Atherosclerosis is a chronic inflammatory disease. Inflam-
mation promotes endothelial cell dysfunction, the influx of
inflammatory white blood cells into the subendothelial
space, and LDL oxidation. As atherosclerotic plaque becomes
progressively more inflamed,it becomes unstable andproneto
rupture. Plaque rupture is responsible for the acute manifes-
tations of atherosclerosis, including myocardial infarction,
unstable angina, and death. While a number of inflammatory
markers may predict increased risk for cardiovascular events,
LpPLA2 exhibits some key differences: Lp-PLA2 is a marker
of vascular-specific inflammation, whereas others biomarkers
such as hs-CRP indicate systemic inflammation. The causal
role of CRP in the progression of atherosclerosis is still being
debated. Serum levels of CRP can vary greatly in response to
a variety of host characteristics, including adiposity/insulin
resistance, infection, rheumatologic disorders, and other
common conditions. Lp-PLA2 participates directly in athero-
genesis by potentiating lipid modification and inflammation.
Lp-PLA2 hydrolyzes phosphatidylcholine to form lysophos-
phatidylcholine and oxidized free fatty acids, both of which
stimulate atherosclerosis. Within individuals, serum levels of
this enzyme have low biovariability and reflect the presence
of rupture prone atherosclerotic plaque in both men and
women. Lp-PLA2 is a valuable discriminator of risk for
cardiovascular disease and can be used to reclassify risk in
patients at intermediate and high risk for cardiovascular
events. Used together, elevations in the serum levels of both
CRP and Lp-PLA2 aid in the refinement and reclassification
of risk [54].
Efforts to identify patients at increased risk for, or with
clinically silent but established, atherosclerotic disease will
intensify, and serum biomarkers will continue to play a crucial
role in the four major domains of screening, diagnosis,
prognosis, and management. Biomarkers, such as Lp-PLA2
levels, may serve a broader role as a prognostic aid and
therapeutic target in atherosclerotic disease management. The
measured levels of the mass and activity of this enzyme
appear to be directly linked to the pathogenesis and
progression of atherosclerosis and, importantly, serum levels
decline in response to therapeutic agents that have been
shown to reduce CHD events, including statins, fibrates,
nicotinic acid, and omega-3 fatty acids. Direct molecular
inhibitors of Lp-PLA2 such as darapladib, if proven to reduce
events, will solidify this marker along with LDL-C, as a key
treatment target in the reduction of cardiovascular risk and the
prevention of myocardial infarction, stroke, and cardiovascu-
lar death. At the present time clinicians tend to use one
inflammatory marker over another when evaluating risk. It is
possible that optimal risk prediction and assignment will
involve a panel of biomarkers that encapsulate both systemic
inflammation and evidence of inflamed, unstable atheroscle-
rotic plaque prone to rupture. The growing body of evidence
points to an important role and utility for Lp-PLA2 testing in
preventive and personalized clinical medicine.
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